BHVN

Biohaven Ltd

Add to Watchlist

Advanced Chart

13.080

-0.42(-3.111%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

13.5738

Open

13.560

VWAP

Vol

1.17M

Mkt Cap

1.38B

Low

13.050

Amount

EV/EBITDA(TTM)

Total Shares

88.29M

1.06B

EV/OCF(TTM)

P/S(TTM)

Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.

10 Analyst Rating

298.55% Upside

Wall Street analysts forecast BHVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHVN is 52.13 USD with a low forecast of 21.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

1 Hold

0 Sell

Strong Buy

298.55% Upside

Current: 13.080

Low

21.00

Averages

52.13

High

75.00

298.55% Upside

Current: 13.080

Low

21.00

Averages

52.13

High

75.00

JPMorgan

Tessa Romero

Overweight

downgrade

$68 -> $55

2025-06-19

Reason

JPMorgan

Tessa Romero

Price Target

$68 -> $55

2025-06-19

downgrade

Overweight

Reason

JPMorgan analyst Tessa Romero lowered the firm's price target on Biohaven to $55 from $68 and keeps an Overweight rating on the shares. The firm updated its model following recent developments for Biohaven. It now models a U.S. launch for troriluzole in spinocerebellar ataxia beginning in Q4 instead of Q3 following the DDA action date extension. JPMorgan also removed revenue contributions from BHV-2100 for acute migraine following the completion of the proof-of-concept Phase 2 trial with no efficacy signal detected.

RBC Capital

Outperform -> Sector Perform

downgrade

$54 -> $21

2025-05-19

Reason

RBC Capital

Price Target

$54 -> $21

2025-05-19

downgrade

Outperform -> Sector Perform

Reason

RBC Capital downgraded Biohaven to Sector Perform from Outperform with a price target of $21, down from $54.

RBC Capital

Outperform -> Sector Perform

downgrade

$54 -> $21

2025-05-19

Reason

RBC Capital

Price Target

$54 -> $21

2025-05-19

downgrade

Outperform -> Sector Perform

Reason

RBC Capital

Leonid Timashev

Outperform

downgrade

$61 -> $54

2025-05-13

Reason

RBC Capital

Leonid Timashev

Price Target

$61 -> $54

2025-05-13

downgrade

Outperform

Reason

RBC Capital analyst Leonid Timashev lowered the firm's price target on Biohaven to $54 from $61 to reflect its cash burn and recent financing but keeps an Outperform rating on the shares after its Q1 results. The firm sees an eventful 2025 for the company as the strategy of multiple parallel phase 3 programs should begin to bear fruit, with phase 3s in MDD - major depressive disorder - and OCD reading out this year, as well as a PDUFA in SCA, spinocerebellar ataxia, all having potential to significantly inflect shares, the analyst tells investors in a research note. The reward/risk is favorable across the totality of Biohaven's pipeline, the firm adds.

Morgan Stanley

Terence Flynn

Buy

Maintains

$69 → $63

2025-03-07

Reason

Morgan Stanley

Terence Flynn

Price Target

$69 → $63

2025-03-07

Maintains

Buy

Reason

JP Morgan

Tessa Romero

Buy

Maintains

$72 → $68

2025-03-05

Reason

JP Morgan

Tessa Romero

Price Target

$72 → $68

2025-03-05

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Biohaven Ltd (BHVN.N) is -1.85, compared to its 5-year average forward P/E of -4.57. For a more detailed relative valuation and DCF analysis to assess Biohaven Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.57

Current PE

-1.85

Overvalued PE

-2.96

Undervalued PE

-6.19

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.67

Current EV/EBITDA

-1.59

Overvalued EV/EBITDA

-0.77

Undervalued EV/EBITDA

-6.58

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

74140.57

Current PS

241.21

Overvalued PS

314274.99

Undervalued PS

-165993.85

Financials

Annual

Quarterly

FY2025Q1

YoY :

+20.91%

-221.56M

Operating Profit

FY2025Q1

YoY :

+23.49%

-221.68M

Net Income after Tax

FY2025Q1

YoY :

-1.36%

-2.17

EPS - Diluted

FY2025Q1

YoY :

+60.64%

-165.59M

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

996.2K

USD

Months

6-9

1.0M

USD

Months

0-12

2.2M

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

317.2K

Volume

6-9

Months

960.3K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

24.4K

Volume

Months

6-9

1.9M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

996.2K

USD

Months

6-9

1.0M

USD

Months

0-12

2.2M

USD

Months

BHVN News & Events

Events Timeline

2025-06-30 (ET)

2025-06-30

11:50:02

FDA flags possible safety signals in new report, says RBC Capital

2025-06-10 (ET)

2025-06-10

14:02:22

Bexorg announces multi-program research collaboration with Biohaven

2025-05-29 (ET)

2025-05-29

07:08:55

Biohaven initiates global Phase 2/3 study of BHV-8000

News

7.0

08:45 AMPRnewswire

BHVN LAWSUIT ALERT: The Gross Law Firm Notifies Biohaven Ltd. Investors of a Class Action Lawsuit and Upcoming Deadline

7.0

07-27PRnewswire

Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN

7.0

07-27Globenewswire

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Biohaven Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BHVN